ISBN 978-1-135-92841-4
Based on these data, the FDA approved tesamorelin (marketed as EGRIFTA) for the reduction of excess abdominal fat in HIVassociated lipodystrophy, not as a general weightloss drug for the wider population. Tesamorelin Risks and Considerations Like all hormonemodulating therapies, tesamorelin carries potential risks, including fluid retention, joint pain, injectionsite reactions, and effects on glucose metabolism in susceptible patients
Nevertheless, certain conditions can impact the absorption or intake, hence often leading to deficiency, for example, pernicious anemia or if the individual follows a vegan diet
Transparency: Our unwavering commitment to transparency and quality sets us apart from competition
Some peptides are studied for their relationship with growth hormones, while others are discussed in relation to weight loss, recovery, and healthy aging
Summary: Elevated vitamin B12 levels rarely cause direct symptoms